Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR)

NCT04647903 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

ADHD
Narcolepsy

Interventions

DRUG: ADAIR 10 mg IR tablets
DRUG: d-amphetamine sulfate
DRUG: Placebo

Sponsor

Vallon Pharmaceuticals, Inc.